NASDAQ:NTRP

Neurotrope (NTRP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.71
$2.93
50-Day Range
$0.92
$1.05
52-Week Range
$0.68
$3.85
Volume
1,453 shs
Average Volume
12,840 shs
Market Capitalization
$2.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NTRP stock logo

About Neurotrope Stock (NASDAQ:NTRP)

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.

NTRP Stock News Headlines

NextTrip Inc NTRP
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Neurotrope, Inc. Common Stock (NTRP)
See More Headlines
Receive NTRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurotrope and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2018
Today
4/23/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Miscellaneous manufacturing industries
Sub-Industry
N/A
Current Symbol
NASDAQ:NTRP
Employees
5
Year Founded
N/A

Profitability

Net Income
$-8,690,000.00
Net Margins
-1,123.90%
Pretax Margin
-1,123.90%

Debt

Sales & Book Value

Annual Sales
$630,000.00
Book Value
$9.67 per share

Miscellaneous

Free Float
679,000
Market Cap
$2.29 million
Optionable
No Data
Beta
1.54
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Charles S. Ryan J.D. (Age 56)
    Ph.D., Chief Exec. Officer and Director
    Comp: $850.21k
  • Dr. Daniel L. Alkon (Age 78)
    Pres & Chief Science Officer
    Comp: $275k
  • Mr. Robert Weinstein (Age 60)
    Chief Financial Officer, Exec. VP, Sec. and Treasurer
    Comp: $423.82k
  • Mr. Jeffrey Benison
    Director of Corp. Communications
  • Dr. Alan J. Tuchman (Age 73)
    Acting Chief Medical Officer

NTRP Stock Analysis - Frequently Asked Questions

When is Neurotrope's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our NTRP earnings forecast
.

How were Neurotrope's earnings last quarter?

Neurotrope, Inc. (NASDAQ:NTRP) issued its earnings results on Tuesday, October, 30th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.05. Neurotrope had a negative net margin of 1,123.90% and a negative trailing twelve-month return on equity of 180.93%.

What other stocks do shareholders of Neurotrope own?
This page (NASDAQ:NTRP) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners